A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

Study Identifier:
ACH171-002
ClinicalTrials.gov Identifier:
NCT00401947
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ACH-0137171
Date
Nov 2006 - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years
Requirements Information
Sex
Female & Male
Age
18 - 60 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: ACH-0137171
Date
Nov 2006 - N/A
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 60 Years years
Requirements Information

Protocol Summary

The purpose of this study was to investigate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of multiple doses of ACH-0137171 in participants with chronic hepatitis C virus (HCV) infection.

Trial Locations

Location
Status
Location
Clinical Trial Site
Phoenix, Arizona, United States, 85054
Status
N/A
Location
Clinical Trial Site
La Jolla, California, United States, 92093
Status
N/A
Location
Clinical Trial Site
San Francisco, California, United States, 94143
Status
N/A
Location
Clinical Trial Site
Boston, Massachusetts, United States, 02215
Status
N/A
Location
Clinical Trial Site
New York, New York, United States, 10029
Status
N/A
Location
Clinical Trial Site
Dallas, Texas, United States, 75208
Status
N/A
Go to page